Mitochondrial Peptides: Why SS-31 and MOTS-c Are Not the Same Thing

Mitochondrial peptides are the newest family of research compounds in wide circulation, and the most commonly misdescribed. SS-31 and MOTS-c are routinely sold beside each other under the same heading — but only one of them is a mitochondrial-derived peptide. They are different classes of molecule with different origins and different mechanisms, and the distinction changes how you read every claim made about either.

Two different things wearing one label

A mitochondrial-derived peptide (MDP) is encoded in mitochondrial DNA rather than nuclear DNA. This is genuinely unusual. Mitochondria carry their own small circular genome — a remnant of the bacterial ancestor that became the organelle — and for decades it was assumed to encode only a handful of respiratory-chain subunits and structural RNAs. The discovery that short open reading frames inside those RNA genes also produce bioactive peptides opened a distinct field.

MOTS-c is one of them. The name stands for mitochondrial open reading frame of the 12S rRNA type-c: a 16-amino-acid peptide encoded within the 12S ribosomal RNA gene of mitochondrial DNA. Humanin, a 24-amino-acid peptide from the 16S rRNA region, was the first MDP identified, in 2001.

SS-31 is not an MDP. It is a synthetic tetrapeptide — four amino acids, designed rather than discovered, from the Szeto-Schiller series developed by Hazel Szeto and Peter Schiller. It is also known as elamipretide, MTP-131 and Bendavia. It is not encoded anywhere in the human genome. What it shares with MOTS-c is a destination, not an origin: both end up acting at the mitochondrion. Grouping them by that shared destination is like grouping a locksmith with a battering ram because both get you through a door.

MOTS-c: a metabolic signal that talks back to the nucleus

The research interest in MOTS-c centres on metabolic regulation. The initial characterisation described effects on the folate-methionine cycle, with downstream consequences for purine biosynthesis and activation of the AMPK pathway — the cell's principal energy-sensing switch, which responds to a falling energy charge by shifting metabolism toward catabolic, energy-generating processes.

The more striking later finding is that MOTS-c does not stay in the mitochondrion. Under metabolic stress it translocates to the nucleus, where it associates with stress-responsive transcription factors and influences nuclear gene expression. That makes it an example of retrograde signalling: information travelling from the mitochondrion back to the nuclear genome, rather than the more familiar direction of nuclear-encoded proteins being imported into mitochondria.

Human observational work has reported that circulating MOTS-c levels change with exercise and vary with age. Observational data of that kind establishes association, not cause — it cannot distinguish a peptide that drives a change from one that merely rises alongside it.

SS-31: a molecule that binds a lipid, not a receptor

SS-31 works by an unusual route. Most signalling peptides bind a protein receptor. SS-31 instead binds cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane.

Cardiolipin matters structurally. It has four acyl chains rather than the usual two, giving it a conical shape that favours the tight curvature of cristae — the folds where oxidative phosphorylation happens. It is also required for the assembly and stability of electron-transport-chain supercomplexes, and it anchors cytochrome c to the inner membrane.

The proposed mechanism is that SS-31 associates with cardiolipin and stabilises the cardiolipin–cytochrome c interaction, limiting the peroxidase activity that cytochrome c can acquire when that association is disrupted. In laboratory models this is described as protecting cristae architecture and improving the efficiency of electron transport under stress. The compound is cell-permeable and concentrates in the inner membrane, which is what makes a four-amino-acid peptide able to act at that site at all.

What the clinical record actually shows

This is where SS-31 differs most from almost every other compound discussed on this site: as elamipretide, it has been through registered clinical trials in humans, in conditions including Barth syndrome, primary mitochondrial myopathy and dry age-related macular degeneration.

That record is genuinely mixed, and the mixed part is the informative part. The MMPOWER-3 trial in primary mitochondrial myopathy did not meet its primary endpoint. A compound with a coherent mechanism, strong preclinical data and real clinical investment can still fail to produce a measurable benefit on a chosen endpoint in a chosen population. Anyone citing SS-31's mechanism as though it settles the question of effect is skipping the only part of the evidence that was designed to answer it.

MOTS-c has no comparable human trial programme. Its literature is preclinical and observational.

How to weigh claims about this family

Three things are worth holding onto:

• Check which molecule is being discussed. Claims about "mitochondrial peptides" often blend MDP findings with SS-31 findings. They are separate literatures and do not transfer.
• Mechanism is not outcome. Cardiolipin binding is well characterised. Whether that produces a clinically meaningful change is a different question, and one trial designed to answer it returned a negative result.
• Note the model. Much of the preclinical work uses ischaemia-reperfusion or genetic disease models. Findings from a system under acute injury do not automatically describe a healthy one.

For the wider framework these compounds sit in, see how peptides work. For verifying what is in a specific vial before any of this matters, see how to vet a certificate of analysis.

TXLABS supplies these compounds strictly as research reference materials for laboratory use only. They are not medicines and are not for human or veterinary use. Nothing here is dosing guidance or a suggestion of use.